The 51st annual meeting of the American society of hematology: New Orleans, LA; December 5-8, 2009

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 1, 2010, Pages 11-20

  Cunningham, Sonia ^a   Muneer, Sabeeha ^a   Ranganathan, Aarati ^a   Shrader, Marissa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLIC ACID; IMATINIB; MELPHALAN; NILOTINIB; PRALATREXATE; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; HEMATOLOGY; HUMAN; HYPOKALEMIA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; MEDICAL SOCIETY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE SPASM; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PLEURA EFFUSION; PROGNOSIS; PRURITUS; QT PROLONGATION; RASH; SECOND CANCER; SIDE EFFECT; SKIN ALLERGY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; ARTICLE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL, PERIPHERAL; MULTIPLE MYELOMA; PREDNISOLONE; VINCRISTINE;

EID: 77954042741     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.001     Document Type: Conference Paper

References (33)

1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-26. (Pubitemid 46211317)
2. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-91.
3. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-7. (Pubitemid 46638950)
4. Pfreundschuh M, Trumper L, Kloess M, et al. Twoweekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104:634-41. (Pubitemid 38970554)
5. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9:105-16.
6. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009; 27(suppl):435s (abstract 8506).
7. Delarue R, Tilly H, Salles G, et al. R-CHOP14 Compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA Study. Paper presented at: the Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA. Abstract 406.
8. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27:1492-501.
9. Leoni LM, Bailey B, Niemeyer CC, et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Am Assoc Cancer Res 2004; 45: (abstract 1215).
10. Kanekal S, Crain B, Elliott G, et al. SDX-105 (bendamustine) inhibits growth of SU-DHL-1 and Daudi lymphoma xenografts in SCID mice. Am Assoc Cancer Res 2004; 45: (abstract 4575).
11. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-9.
12. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4473-9.
13. Rummel MJ, Nierderle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as firstline treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) Blood 2009; 114:168 (abstract 405).
14. O'Leary H, Savage KJ. The spectrum of peripheral T-cell lymphomas. Curr Opin Hematol 2009; 16:292-8.
15. Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 2008; 11:508-21. (Pubitemid 351950864)
16. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27:4357-64.
17. O'Connor O A, Pro B, Pinter-Brown L. PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). J Clin Oncol 2009; 27 (suppl):449s (abstract 8561).
18. Pro B, Coiffier B, Horwitz S, et al. Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis. Blood 2009; 114:670 (abstract 1681).
19. Pinter-Brown L, Horwitz S, Pro B, et al. Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). Blood 2009; 114:668 (abstract 1675).
20. Savage KJ, Shustov AR, Goy A, et al. Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL). Blood 2009; 114:669 (abstract 1678).
21. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114:462 (abstract 1126).
22. Saglio G, Kim D-W, S. I, et al. Nilotinib demonstrates superior efficacy compared withimatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial. Blood 2009; 114: (abstract LBA-1).
23. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009; 374:324-39.
24. Mateos M-V, Richardson P, Schlag R, et al. Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit Vs elphalanprednisone in the phase III VISTA trial in previously untreated multiple myeloma after 3 years' follow-up and extensive subsequent therapy use. Blood 2009; 114:1484 (abstract 3859).
25. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27:1788-93.
26. Cavo M, Pantani L, Tacchetti P, et al. Thalidomide maintenance in multiple myeloma: certainties and controversies. J Clin Oncol 2009; 27:e186-7.
27. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99:3163-8. (Pubitemid 34525294)
28. Mateos M-V, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/ melphalan/prednisone (VMP) versus bortezomib/ thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/ thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. Blood 2009; 114:3 (abstract 3).
29. Venon MD, Roccaro AM, Gay J, et al. Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics 2009; 3:99-109.
30. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906-17.
31. Mateos M-V, Richardson P, Schlag R, et al. Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit vs melphalan- prednisone in the phase III VISTA trial in previously untreated multiple myeloma after 3 years' follow-up and extensive subsequent therapy use. Presented at: the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2010; New Orleans, LA. Abstract 3859.
32. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109:2767-72. (Pubitemid 46482069)
33. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients. Presented at: the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2010; New Orleans, LA. Abstract 128.